[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma

In the second interim analysis of the randomised phase 3 ENDEAVOR study published in The Lancet Oncology, Meletios Dimopoulos and colleagues1 found that, with long-term follow-up, patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone (median 47·6 months [95% CI 42·5-not evaluable]) had significantly longer overall survival than those who were treated with bortezomib and dexamethasone (40·0 months [32·6–42·3]; hazard ratio 0·791 [95% CI 0·648–0·964]). Although the study was done as an open-label study because of the different dosing schedules for the two proteasome inhibitors, baseline clinical and treatment characteristics, including various prognostic factors and subsequent antimyeloma therapies, were generally balanced between groups.

http://ift.tt/2C8XZ0m